Tigecycline

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Glycylclin antibiotic (tetracycline derivative). Broad-spectrum antibiotic.

Pharmacodynamics (Effect)This section has been translated automatically.

  • Binding to the 30S subunit of the bacterial ribosomes. This inhibits the translation of bacterial protein synthesis by preventing the attachment of aminoacyl-tRNA molecules to the ribosomal acceptor site (A-site). This prevents the incorporation of amino acid residues into growing peptide chains.
  • Glycylcyclins circumvent the two essential resistance mechanisms of bacteria (efflux pumps and ribosomal protection mechanisms). Efflux pumps cause the antibiotic to be rapidly pumped out of the bacteria, which considerably reduces the effectiveness of the antibiotic. Ribosomal protection mechanisms prevent antibiotics from interfering with the protein synthesis of the bacteria.
  • Notice! Tigecycline is sensitive to the chromosomal multidrug efflux pumps of Proteae (Proteus spp., especially P. mirabilis, P. vulgaris and P. myxofaciens as well as Morganella spp., especially Morganii and Providencia spp., especially P. rettgeri, P. alcalifaciens and P. stuartii) and Pseudomonas aeruginosa (MexXYOprM efflux system). Here there are 2 gaps in effectiveness.

Spectrum of actionThis section has been translated automatically.

Particularly broad spectrum of action against gram-positive and gram-negative, aerobic and anaerobic as well as atypical pathogens and multi-resistant germs. Effective against MRSA, ORSA, vancomycin-resistant enterococci, tetracycline-resistant pathogens, Acinetobacter spp

.

Tigecycline is not effective against Pseudomonas aeruginosae.

IndicationThis section has been translated automatically.

Complicated skin and soft tissue infections. Complicated intra-abdominal infections. S.a.u. ESBL.

Pregnancy/nursing periodThis section has been translated automatically.

There are not sufficient data available for the use of tigecycline in pregnant women or lactating women. According to animal studies, tigecycline can cause fetal damage during pregnancy. Like antibiotics of the tetracycline group, tigecycline can cause permanent tooth damage (discoloration and loss of enamel) and delay bone formation in the foetus in the last half of pregnancy and in children under 8 years of age.

Dosage and method of useThis section has been translated automatically.

Initial 100 mg IV followed by 50 mg IV every 12 hours over a period of 5-14 days.

Undesirable effectsThis section has been translated automatically.

Passengers nausea and vomiting (usually at the beginning of treatment). There is insufficient data for the use of tigecycline in pregnant women.

ContraindicationThis section has been translated automatically.

Do not use on children, especially not on children under 8 years of age.

PreparationsThis section has been translated automatically.

Tygacil

Authors

Last updated on: 29.10.2020